Kadcyla Positioned For Wide Use In Metastatic Breast Cancer
Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line+ mBC, but labeling allows first-line treatment in a subset of patients at high risk.
You may also be interested in...
"Tipping point" occurred when Phigenix changed theory that Genentech's Kadcyla infringed its patent; CEO may be on hook for attorneys' fees.
In a surprising move, Roche has decided to give up its patents for Herceptin in India, leaving the way open for generic drug makers eyeing the booming market. But do any local firms have the capabilities to develop and manufacture a biosimilar of trastuzumab?
Roche CEO Severin Schwan says the Swiss group’s recent revamps, lack of patent expiries, and ongoing drug innovations give the world’s largest maker of cancer drugs a strong position to expand its sales globally, helped by new cutting-edge therapies and creative business approaches.